Despite Projections of a 2024 Adalimumab Biosimilar Boom, Humira Remains Dominant for Now, According to Spherix Global Insights
EXTON, PA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights compiled data from their RealTime Dynamix™ services in Crohn’s Disease, Rheumatoid Arthritis, and Psoriasis, fielded in late April 2024 (n=104 gastroenterologists, 103 rheumatologists, …